We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-19.24%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$116M
Cap. Flow
-$68.3M
Cap. Flow %
-58.19%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
5
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$29.1M
2
APLS
Apellis Pharmaceuticals
APLS
+$17.7M
3
AKRO
Akero Therapeutics
AKRO
+$17M
4
VRNA
Verona Pharma
VRNA
+$2.3M
5
DTIL icon
Precision BioSciences
DTIL
+$2.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
1
DELISTED
Akero Therapeutics
AKRO
$66.8M 56.91%
3,150,019
-790,524
-20% -$17M
DTIL icon
2
Precision BioSciences
DTIL
$215M
$24.2M 20.6%
133,597
-8,574
-6% -$2.24M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$13.4M 11.45%
501,584
-498,416
-50% -$17.7M
TPTX
4
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.16M 6.1%
160,333
-547,900
-77% -$29.1M
YARW
5
Yarrow Bioscience
YARW
$98.8M
$3.92M 3.34%
406
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$1.88M 1.6%
456,770
-418,230
-48% -$2.3M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q1 2020 Portfolio in Review

As of Q1 2020, venBio Partners held 6 positions worth $117M, down 50% from $233M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $68.3M in Q1 2020, reducing 5 holdings. Its largest reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q1 2020 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $29.1M.
  • venBio Partners's ten largest holdings make up 100% of its $117M portfolio in Q1 2020.
  • venBio Partners opened 0 new positions and closed 0 in Q1 2020.
  • venBio Partners's portfolio value fell 50% quarter-over-quarter to $117M.

Based on venBio Partners's 13F filing for Q1 2020, filed 15 May 2020.